High Dose Oxytocin Nasal Spray for Treatment of Tinnitus

Tinnitus Clinical Trial

Official title:

A Pilot, Proof of Concept, Placebo-controlled, Parallel Study of the Effects of High Dose Intranasal Oxytocin for the Treatment of Tinnitus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04210310
• Other study ID #: 19-01381
• Status: Terminated
• Phase: Phase 3
• Start date: January 15, 2020
• Est. completion date: May 10, 2022

Study information

• Verified date: September 2022
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability.

Description:

This is a pilot, proof of concept, placebo-controlled, parallel study. Participants will be recruited from NYU Langone Medical Center's Ear, Nose & Throat (ENT) Department and will receive either high-dose intranasal oxytocin or a nasal spray containing Pcca Mucolox and distilled water, serving as the placebo. Long term treatment with high-dose oxytocin (45 IU four times daily) may reduce the frequency and severity of tinnitus, the burden tinnitus symptoms cause patients, and improve their quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 33
• Est. completion date: May 10, 2022
• Est. primary completion date: May 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects with continuous perception of subjective tinnitus for = 6 months duration.

• Subjects must have had a normal otolaryngologic evaluation within the past year with no evidence of otitis media or externa, a Tinnitus Handicap Inventory (THI) of > 16.

• Subjects must have tinnitus loudness rating of >4/10.

Exclusion Criteria:

• Subjects who are being treated for tinnitus < 6 months due to the acute nature of their condition

• Subjects who have a slight handicap according to the Tinnitus Handicap Inventory Severity Scale.

• Those with tinnitus of a muscular or vascular etiology

• Subjects with conductive hearing loss, history of migraine, or prior use of oxytocin nasal spray.

• Women of childbearing age will not be approached for participation due to the risk of oxytocin-induced uterine contractions.

• Subjects who suffer from migraines.

• Subjects who have history of pulmonary edema, Congestive Heart Failure, and severe renal disease.

Related Conditions & MeSH terms

• Tinnitus

Intervention

Drug:
• Oxytocin
The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day

Other:
• Placebo nasal spray
A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.

Locations

Country	Name	City	State
United States	222 East 41st Street Ambulatory Care Center, Preston Robert Tisch Center for Men's Health	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Visual Analogue Scale (VAS)-Rated Tinnitus Loudness	Participants use a VAS to rate the loudness of tinnitus on an 11-point Likert scale. Total scores range from 0 (minimum) to 10 (maximum); higher scores indicate greater tinnitus loudness.; No response to nasal spray is defined as a decrease in VAS Score of less than 2, while a patient-reported improvement is defined as a decrease in VAS Score of more than 3.	Baseline, Week 9